Innovation Pharmaceuticals develops small molecule therapies to treat cancer, antibiotics, and inflammatory disease. The company focuses on the development of compounds, including Kevetrin, an anti-cancer compound that has completed Phase I clinical trial; and Prurisol, an anti-psoriasis drug candidate that is in Phase II clinical trial. It also focuses on the development of Brilacidin, an antibiotic candidate for the treatment of acute bacterial skin and skin structure infection, oral mucositis, and inflammatory bowel disease, and ulcerative proctitis/colitis; and defensin-mimetics for otic infections, diabetic foot infections, and hidradenitis suppurativa indications.
TypePublic
HQBeverly, US
Founded2007
Size (employees)15 (est)
Websiteipharminc.com
Innovation Pharmaceuticals was founded in 2007 and is headquartered in Beverly, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Innovation Pharmaceuticals

Leo Ehrlich

Leo Ehrlich

CEO
Arthur Bertolino

Arthur Bertolino

President
Show more

Innovation Pharmaceuticals Office Locations

Innovation Pharmaceuticals has an office in Beverly
Beverly, US (HQ)
151 100 Cummings Center
Show all (1)
Report incorrect company information

Innovation Pharmaceuticals Financials and Metrics

Innovation Pharmaceuticals Revenue

USD

Net income (FY, 2018)

(16.4 m)

EBIT (FY, 2018)

(13.9 m)

Market capitalization (19-Sep-2018)

40.7 m

Cash (30-Jun-2018)

2.4 m
Innovation Pharmaceuticals's current market capitalization is $40.7 m.
Annual
USDFY, 2016FY, 2018

General and administrative expense

1.9 m1.4 mwdxefcqufszuzezftuxetqsqxt

R&D expense

9 m11.4 m

Operating expense total

10.9 m13.9 m

EBIT

(12.7 m)(13.9 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

General and administrative expense

244 k275 k339 k352 k249 k362 k344 k331 k889 k

R&D expense

1.9 m2.3 m1.8 m2.1 m3 m2.3 m2.7 m3.2 m9.5 m

Operating expense total

2.2 m2.6 m2.2 m2.5 m3.3 m2.6 m3 m3.5 m11.4 m

EBIT

(2.7 m)(2.8 m)(2.5 m)(3.3 m)(3.7 m)(3 m)(3.3 m)(3.9 m)(11.4 m)
Annual
USDFY, 2016FY, 2018

Cash

6.3 m2.4 m

Current Assets

6.7 m2.6 m

Total Assets

11.4 m6.5 m

Accounts Payable

42.2 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q3, 2018

Cash

7.1 m9.5 m10.8 m7.8 m6.2 m5.3 m1.3 m

Current Assets

7.2 m9.6 m11.4 m8 m6.4 m5.8 m1.5 m

Total Assets

12.5 m14.9 m17.1 m13.5 m11.9 m11.3 m5.8 m

Current Liabilities

8 m7.7 m7.3 m7.5 m7.6 m8.4 m9.5 m
Annual
USDFY, 2016FY, 2018

Net Income

(12.9 m)(16.4 m)

Accounts Payable

1.7 m(1.5 m)

Cash From Operating Activities

(9.9 m)(13.3 m)

Purchases of PP&E

(68 k)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(2.8 m)(2.9 m)(2.6 m)(3.3 m)(3.7 m)(3 m)(3.4 m)(3.9 m)
USDY, 2018

Financial Leverage

-3 x
Show all financial metrics
Report incorrect company information

Innovation Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Innovation Pharmaceuticals News and Updates

Innovation Pharmaceuticals to Present Brilacidin for Inflammatory Bowel Disease at Inaugural “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation

BEVERLY, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company has been invited to present on the planned continued development of Brilacidin for Inflammatory Bowel Disease at …
Report incorrect company information

Innovation Pharmaceuticals Company Life and Culture

Report incorrect company information